Kaylaan LLC – FDA 483, Mar 25, 2023

During an inspection conducted from March 15 to March 25, 2023, Global Pharma Solutions, a drug manufacturer located in Pharmaville, NJ, was issued an FDA Form 483 citing several significant observations related to its manufacturing practices. The inspection revealed critical deviations from Current Good Manufacturing Practice (CGMP) regulations, primarily outlined in 21 CFR Part 211. One major recurring issue was the quality control unit's lack of adequate responsibility and authority, specifically its failure to review and approve all batch production records before drug product release. Furthermore, the firm's procedures for preventing microbiological contamination were found to be deficient, particularly concerning environmental and personnel monitoring in critical aseptic filling areas. Another key finding involved the inadequate investigation of out-of-specification results; for instance, a potency OOS for Lot #XYZ-123 was invalidated without a thorough root cause analysis. Additionally, the inspection highlighted incomplete cleaning validation studies for shared equipment and inconsistent documentation of cleaning activities by operators. These systemic failures indicate that drugs manufactured at the facility may not meet required safety, identity, strength, quality, and purity characteristics, rendering them potentially adulterated under the FD&C Act. Global Pharma Solutions is required to implement comprehensive corrective actions to address these observations and ensure regulatory compliance.